Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma

Timothy G. Murray, Nicole Cicciarelli, Joan M. O'Brien, Eleiit Hemändez, Rachel L. Mueller, Barbara Smith, William J Feuer

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Objectives: To determine the efficacy and dose response of subconjunctival carboplatin with and without cryotherapy in the treatment of murine transgenic hereditary retinoblastoma. Methods: Fifty-one 5-week-old transgenic BLH SV-40 (Charles Rivers Laboratories, Boston, Mass) T-antigen- positive mice with retinoblastoma were administered 6 subconjunctival injections of carboplatin in 1 eye at drug doses of 10, 15, 20, 25, 62.5, 125, and 250 μg. Six control eyes received 6 subconjunctival injections of balanced salt solution. Fourteen of the 51 subconjunctivally treated eyes received a single application of transconjunctival cryotherapy immediately prior to each carboplatin injection. Six control eyes received 6 single applications of transconjunctival cryotherapy using the above schedule but did not receive carboplatin. All experimental and control eyes were obtained at 16 weeks of age for histopathologic examination. Results: A dose-dependent inhibition of intraocular tumor growth by subconjunctivally delivered carboplatin was observed in these transgenic retinoblastoma mice. Tumor development was inhibited in 50% of the mouse eyes at doses of 180 μg. In animals treated with cryotherapy alone, no tumor control was noted (0 of 6). In animals treated with subconjunctival carboplatin coupled with cryotherapy, a tumor control dose of 417 μg was found. No evidence of histopathologic treatment toxicity was noted. Conclusions: Subconjunctival delivery of carboplatin in serial doses effectively inhibits intraocular tumor growth in a dose-dependent fashion in a transgenic murine retinoblastoma model. Cryotherapy does not increase tumor control in this murine retinoblastoma model.

Original languageEnglish (US)
Pages (from-to)1286-1290
Number of pages5
JournalArchives of Ophthalmology
Volume115
Issue number10
StatePublished - 1997

Fingerprint

Cryotherapy
Retinoblastoma
Carboplatin
Neoplasms
Therapeutics
Injections
Viral Tumor Antigens
Growth
Rivers
Transgenic Mice
Appointments and Schedules
Salts
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Murray, T. G., Cicciarelli, N., O'Brien, J. M., Hemändez, E., Mueller, R. L., Smith, B., & Feuer, W. J. (1997). Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Archives of Ophthalmology, 115(10), 1286-1290.

Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. / Murray, Timothy G.; Cicciarelli, Nicole; O'Brien, Joan M.; Hemändez, Eleiit; Mueller, Rachel L.; Smith, Barbara; Feuer, William J.

In: Archives of Ophthalmology, Vol. 115, No. 10, 1997, p. 1286-1290.

Research output: Contribution to journalArticle

Murray, TG, Cicciarelli, N, O'Brien, JM, Hemändez, E, Mueller, RL, Smith, B & Feuer, WJ 1997, 'Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma', Archives of Ophthalmology, vol. 115, no. 10, pp. 1286-1290.
Murray TG, Cicciarelli N, O'Brien JM, Hemändez E, Mueller RL, Smith B et al. Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Archives of Ophthalmology. 1997;115(10):1286-1290.
Murray, Timothy G. ; Cicciarelli, Nicole ; O'Brien, Joan M. ; Hemändez, Eleiit ; Mueller, Rachel L. ; Smith, Barbara ; Feuer, William J. / Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. In: Archives of Ophthalmology. 1997 ; Vol. 115, No. 10. pp. 1286-1290.
@article{d1d5dabfedac4824b31846645941396f,
title = "Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma",
abstract = "Objectives: To determine the efficacy and dose response of subconjunctival carboplatin with and without cryotherapy in the treatment of murine transgenic hereditary retinoblastoma. Methods: Fifty-one 5-week-old transgenic BLH SV-40 (Charles Rivers Laboratories, Boston, Mass) T-antigen- positive mice with retinoblastoma were administered 6 subconjunctival injections of carboplatin in 1 eye at drug doses of 10, 15, 20, 25, 62.5, 125, and 250 μg. Six control eyes received 6 subconjunctival injections of balanced salt solution. Fourteen of the 51 subconjunctivally treated eyes received a single application of transconjunctival cryotherapy immediately prior to each carboplatin injection. Six control eyes received 6 single applications of transconjunctival cryotherapy using the above schedule but did not receive carboplatin. All experimental and control eyes were obtained at 16 weeks of age for histopathologic examination. Results: A dose-dependent inhibition of intraocular tumor growth by subconjunctivally delivered carboplatin was observed in these transgenic retinoblastoma mice. Tumor development was inhibited in 50{\%} of the mouse eyes at doses of 180 μg. In animals treated with cryotherapy alone, no tumor control was noted (0 of 6). In animals treated with subconjunctival carboplatin coupled with cryotherapy, a tumor control dose of 417 μg was found. No evidence of histopathologic treatment toxicity was noted. Conclusions: Subconjunctival delivery of carboplatin in serial doses effectively inhibits intraocular tumor growth in a dose-dependent fashion in a transgenic murine retinoblastoma model. Cryotherapy does not increase tumor control in this murine retinoblastoma model.",
author = "Murray, {Timothy G.} and Nicole Cicciarelli and O'Brien, {Joan M.} and Eleiit Hem{\"a}ndez and Mueller, {Rachel L.} and Barbara Smith and Feuer, {William J}",
year = "1997",
language = "English (US)",
volume = "115",
pages = "1286--1290",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma

AU - Murray, Timothy G.

AU - Cicciarelli, Nicole

AU - O'Brien, Joan M.

AU - Hemändez, Eleiit

AU - Mueller, Rachel L.

AU - Smith, Barbara

AU - Feuer, William J

PY - 1997

Y1 - 1997

N2 - Objectives: To determine the efficacy and dose response of subconjunctival carboplatin with and without cryotherapy in the treatment of murine transgenic hereditary retinoblastoma. Methods: Fifty-one 5-week-old transgenic BLH SV-40 (Charles Rivers Laboratories, Boston, Mass) T-antigen- positive mice with retinoblastoma were administered 6 subconjunctival injections of carboplatin in 1 eye at drug doses of 10, 15, 20, 25, 62.5, 125, and 250 μg. Six control eyes received 6 subconjunctival injections of balanced salt solution. Fourteen of the 51 subconjunctivally treated eyes received a single application of transconjunctival cryotherapy immediately prior to each carboplatin injection. Six control eyes received 6 single applications of transconjunctival cryotherapy using the above schedule but did not receive carboplatin. All experimental and control eyes were obtained at 16 weeks of age for histopathologic examination. Results: A dose-dependent inhibition of intraocular tumor growth by subconjunctivally delivered carboplatin was observed in these transgenic retinoblastoma mice. Tumor development was inhibited in 50% of the mouse eyes at doses of 180 μg. In animals treated with cryotherapy alone, no tumor control was noted (0 of 6). In animals treated with subconjunctival carboplatin coupled with cryotherapy, a tumor control dose of 417 μg was found. No evidence of histopathologic treatment toxicity was noted. Conclusions: Subconjunctival delivery of carboplatin in serial doses effectively inhibits intraocular tumor growth in a dose-dependent fashion in a transgenic murine retinoblastoma model. Cryotherapy does not increase tumor control in this murine retinoblastoma model.

AB - Objectives: To determine the efficacy and dose response of subconjunctival carboplatin with and without cryotherapy in the treatment of murine transgenic hereditary retinoblastoma. Methods: Fifty-one 5-week-old transgenic BLH SV-40 (Charles Rivers Laboratories, Boston, Mass) T-antigen- positive mice with retinoblastoma were administered 6 subconjunctival injections of carboplatin in 1 eye at drug doses of 10, 15, 20, 25, 62.5, 125, and 250 μg. Six control eyes received 6 subconjunctival injections of balanced salt solution. Fourteen of the 51 subconjunctivally treated eyes received a single application of transconjunctival cryotherapy immediately prior to each carboplatin injection. Six control eyes received 6 single applications of transconjunctival cryotherapy using the above schedule but did not receive carboplatin. All experimental and control eyes were obtained at 16 weeks of age for histopathologic examination. Results: A dose-dependent inhibition of intraocular tumor growth by subconjunctivally delivered carboplatin was observed in these transgenic retinoblastoma mice. Tumor development was inhibited in 50% of the mouse eyes at doses of 180 μg. In animals treated with cryotherapy alone, no tumor control was noted (0 of 6). In animals treated with subconjunctival carboplatin coupled with cryotherapy, a tumor control dose of 417 μg was found. No evidence of histopathologic treatment toxicity was noted. Conclusions: Subconjunctival delivery of carboplatin in serial doses effectively inhibits intraocular tumor growth in a dose-dependent fashion in a transgenic murine retinoblastoma model. Cryotherapy does not increase tumor control in this murine retinoblastoma model.

UR - http://www.scopus.com/inward/record.url?scp=0030769835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030769835&partnerID=8YFLogxK

M3 - Article

C2 - 9338675

AN - SCOPUS:0030769835

VL - 115

SP - 1286

EP - 1290

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 10

ER -